Transcriptomic Biomarkers for Individual Risk Assessment
in New-Onset Heart Failure T he clinical course of patients with newly diagnosed heart failure varies drastically, with some patients recovering and returning to completely normal levels of ejection fraction, 1,2 whereas others develop severe symptoms of cardiac decompensation that require insertion of a left ventricular assist device (LVAD) or a heart transplant. 3, 4 Accurate risk assessment and prediction of prognosis at first presentation are crucial for appropriate allocation of therapy, 4, 5 monitoring, 3, 6 and patient management. 1, 7 Prediction tools based on standard criteria have had limited accuracy. 8 -11 In the present study, we present a transcriptome-based biomarker (TBB), 5, 7 which has been derived from a single endomyocardial biopsy sample (EMB) and which predicts the long-term clinical outcome of patients with idiopathic dilated cardiomyopathy (IDCM) with very high accuracy.
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Methods
Patients
EMBs were collected from patients who were referred to Johns Hopkins Hospital between 1997 and 2006 for evaluation of cardiomyopathy (nϭ350). 3 A clinical database of patient outcome was maintained concurrently for a 10-year period beginning in 1997. All patients gave written informed consent for sample collection and medical chart abstraction. Transvenous EMBs from the right ventricular septum were obtained as described previously 3 for subsequent microarray analysis. To avoid possible disease-specific confounding factors, only samples from patients with IDCM were selected. IDCM was a diagnosis of exclusion after extensive histological workup without any detectable pathological signs. 4 Within a repository of 180 IDCM samples, biopsy samples were selected in a case-control fashion based on the phenotypic extremes in survival of the cohort. 12 A group with good prognosis (nϭ25) was defined as having event-free survival for at least 5 years after initial presentation with heart failure symptoms; a group with poor prognosis (nϭ18) experienced an event within the first 2 years. Events included death (nϭ14), requirement for an LVAD (nϭ2), or cardiac transplantation (nϭ2).
Processing of Biopsy Samples
EMBs were immediately flash-frozen in liquid nitrogen for storage in a biorepository. All steps of RNA isolation and processing were performed according to MIAME guidelines (Minimum Information About a Microarray Experiment). Tissue samples (average diameter Ϸ2 mm) were homogenized with the MM 301 Mixer Mill (Retsch, Inc, Newtown, Pa; catalog No. 85120). Trizol reagent together with the Micro-to-Midi Total RNA Purification System (Invitrogen, Carlsbad, Calif; catalog No. 12183-018) was used for extraction of total RNA (success rate 97% of samples). Concentration and integrity of total RNA were measured with the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc, Santa Clara, Calif). All RNA samples exhibited intact 28S and 18S ribosomal RNA on denaturing agarose gel electrophoresis, and the 260/280-nm absorbance readings fell within the acceptable range of 1.8 to 2.1. An average of 568Ϯ92 ng (meanϮSEM) of total RNA was isolated and preprocessed with the Ovation Biotin RNA Amplification and Labeling System (NuGEN Technologies, Inc, San Carlos, Calif; catalog No. 2300-12). 13 
Microarray Hybridization
Samples were hybridized to the Human Genome U133 Plus 2.0 Array from Affymetrix (Santa Clara, Calif) without additional amplification steps. We judged the microarray experiments to be successful when RNA isolation and microarray hybridization met all the indices of quality control as specified in the Affymetrix guidelines for assessing sample and array quality. 7 Average background and noise of all chips registered within acceptable ranges, and hybridization efficiencies were similar for all samples.
Statistical Analysis
Raw intensity values from microarray hybridization were normalized with the robust multiarray average implemented in the R package for statistical computing (available at www.R-project.org). In the next step, significance analysis of microarrays 14 was used to identify phenotype-specific differences in gene expression. Significance analysis of microarrays defines significance with the q value, an adjusted probability value for multiple comparisons. For the development of a TBB, we used prediction analysis of microarrays 15 to create a classifier in a training set (containing two thirds of the data, nϭ29), with subsequent validation in a test set (containing one third of the data, nϭ14). 16 Prediction analysis of microarrays is software that enables one to find the minimum number of genes necessary to create a phenotype-specific "nearest shrunken centroid" for classification. 15 This is done by a balanced 10-fold cross-validation in a training set, which enables one to choose a threshold that minimizes classification errors. 15 Overall accuracy of the discovered transcriptomic biomarker was assessed after 50 random partitions. To test for balanced baseline conditions of the cohort with good versus poor prognosis, we used Student's t test for numerical variables and Fisher's exact test for categorical variables.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
We sought to test the hypothesis that the transcriptome, derived from a single EMB, contains sufficient information to develop a biomarker for prognosis in heart failure. Although substantial research has demonstrated the prognostic value of a variety of biomarkers and clinical prediction algorithms in heart failure, 17,18 the ability to distinguish individual patients who will improve their functional status from those who will go on to circulatory collapse and require cardiac transplantation or LVAD placement remains an important clinical challenge. 1, 3 
Patient Characteristics
A total of 43 EMBs were analyzed with microarray technology to identify phenotype-specific differences in gene expression and to develop a prognostic TBB. Table 1 contains the baseline conditions of both cohorts, patients with good prognosis and those with poor prognosis. Importantly, there were no significant differences in age, gender, ventricular function, hemodynamics, or drug therapy between the 2 groups. The overall population with IDCM presented at an average age of 46Ϯ15 years, with slight overrepresentation of males (67%). Most patients were at an advanced New York Heart Association classification stage (at least stage II), with severely compromised ejection fraction of 23Ϯ13%, average left ventricular internal diastolic dimension of 6.1Ϯ1.5 cm, and pulmonary capillary wedge pressure of 15Ϯ9 mm Hg.
Microarray Analysis
An average of 568Ϯ92 ng (meanϮSEM) of total RNA was isolated from all EMBs and tested with the Agilent 2100 Bioanalyzer, which revealed high integrity and purity of RNA of all samples with consistent bands of 18S and 28S RNA ( Figure 1 ). There were 46 significantly overexpressed genes in patients who recovered from heart failure (qϽ5%, fold change Ͼ1.2; Table 2 ), as determined with significance analysis of microarrays. Prediction analysis of microarrays was used to evaluate the predictive value of this set of genes. To achieve this and to test for validity, patients were allocated into training sets that consisted of two thirds of samples (nϭ29) and test sets that contained one third of samples (nϭ14; Figure 2 ). This approach resulted in a "nearest shrunken centroid" of 45 genes, which distinguished with high accuracy between high-risk patients and those with an excellent prognosis.
Validation
To evaluate the overall performance of the transcriptomic biomarker, we performed 50 random partitions into training and test sets. This approach revealed an overall sensitivity of 74% (95% CI 69% to 79%) and an overall specificity of 90% (95% CI 87% to 93%). The positive predictive value was 85% (95% CI 80% to 89%), whereas the negative predictive value was 82% (95% CI 78% to 86%). The log OR for having an event if classified with poor prognosis was 3.3.
The molecular signature was illustrated in a heat map, which was created by euclidean distance (Figure 3 ). This independent approach of unsupervised clustering additionally confirmed the robustness of the discovered set of genes, with very clear distinction of samples with poor prognosis from those with good prognosis. Pathways with major involvement were ion transport mechanisms (13%), neuromuscular development (10%), protein binding (15%), and transcription (26%; www.geneontology.org; Figure 4 ).
Prediction of Recovery in Left Ventricular Function
Improved clinical outcome is often associated with recovery in left ventricular function. Accordingly, we tested the hypothesis that the good prognosis signature would be associated with improved ejection fraction. Among the study sample (nϭ43), we selected all subjects in whom paired echocardiography data from baseline and follow-up were available (nϭ17) and characterized them as good prognosis or poor prognosis according to their TBB ( Figure 5 ). Patients classified as having good prognosis experienced a substantial improvement in ejection fraction, from 23Ϯ3% to 42Ϯ5% (Pϭ0.0009), whereas patients with a poor prognosis molecular signature continued to have a depressed ejection fraction, with 20Ϯ3% and 21Ϯ3% at baseline and follow-up, respectively.
Discussion
One of the most valuable applications of genomic information has proven to be clinical prediction. 5 Whereas the pattern of differentially expressed genes provides insight into disease origin, 19 it has also been used for the development of biomarkers. 20 This approach has been highly successful in neoplastic disease 15, 20, 21 and is emerging in a variety of other disease processes. 6, 16 Here, we sought to identify a TBB that predicted the clinical outcome of patients with new-onset heart failure. Using a repository of EMBs collected over a 10-year period, 3 we have developed a highly accurate prognostic biomarker that distinguishes patients with very poor trajectory from those with excellent long-term prognosis. Importantly, the present study used biopsy samples from patients presenting at an early disease stage, without additional amplification of RNA.
The present findings address a major unmet need in the management of heart failure: the ability to accurately assess patient prognosis. 1 Although there are emerging biomarkers 17, 18 and clinical prediction algorithms 9,11 of prognostic value, these markers do not dichotomize substantially between patients with highly variable outcomes. 3,8 -11 It has long been known that patients with near-identical features at presentation, receiving identical therapy, can have dramatically differing prognoses. 1,2,4 Although some patients undergo complete recovery of their heart function within an average of 5 years, others progress into circulatory collapse within the first 2 years of presentation and require aggressive therapeutic interventions, such as mechanical circulatory assistance or cardiac transplantation. 3 The ability to predict these patients has great clinical value in an era of multiple therapeutic options.
Previous transcriptomic studies 16, [22] [23] [24] investigated heart tissue from explanted hearts or LVAD. The results of these studies continue to be controversial and have led to the questioning of the feasibility of TBBs in cardiovascular disorders. 23 Many previous studies evaluated gene expression changes during left ventricular functional recovery with mechanical circulatory assistance to discover genes associated with recovery. This approach is inherently limited, because gene expression changes could be either causative or due to a bystander effect of volume unloading. 23, 25 Although Hall et al 22 discovered a molecular signature of recovery that was specific for patients who recovered from heart failure during LVAD placement versus patients who continued to be dependent on a device, Margulies et al 23 concluded from a similarly designed study that transcriptomic changes in recovering LVAD patients would not consistently explain their functional improvement. These controversial findings moti- 
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vated the present study with biopsy samples obtained at the time of patient presentation. Other investigators have attempted TBB studies from explanted hearts rather than LVAD patients. Steenman et al 24 investigated samples with ischemic cardiomyopathy versus IDCM and failed to find significant differences in gene expression. However, that study was limited by an extremely small sample size (nϭ2 in each group), and data were evaluated by pooling the RNA from these samples. This negative finding highlights the importance of sample size in microarray experiments. Learning-curve constructions provided evidence that 20 to 30 samples are required per training set to achieve significance in a classification problem. 26 In a previous study that involved a larger number of samples (nϭ48), we discovered a cluster of genes that accurately distinguished idiopathic from ischemic cardiomyopathy. 16 Several features of this approach may have contributed to the present results. First, the present study used biopsy samples obtained at the time of patient presentation, not taken from explanted hearts, a time at which disease could be considered end-stage. Arguably this approach reduces transcriptomic changes that could be considered compensatory and that could have been activated during disease progression. 23, 25 A second key issue results from our technical approach: We used a highly efficient RNA processing technique that allowed microarray analysis without additional amplification and thus avoided possible bias due to different binding preferences of primers and reduction of time and costs with regard to a later clinical application. 27 The transcriptomic biomarker reported here for cardiomyopathy has a similar degree of accuracy as those developed for cancer. 15, 20, 21 Previous proof-of-concept studies suggested the feasibility of obtaining clinically useful TBBs from cardiac biopsy samples. 16 In this regard, we previously demonstrated in explanted heart tissue obtained at the time of heart transplantation that a transcriptomic signature could be developed to delineate between ischemic and nonischemic cardiomyopathy. 16 Additional support for the concept of TBBs for heart muscle disease arises from the successful development of expression profiles to detect cardiac inflammation. 6, 28 The developed TBB, which contains a molecular signature of 45 genes, predicted the clinical phenotype of samples with very high specificity (90%), which suggests its utility, particularly as a rule-out test in addition to current standard risk assessment. Furthermore, results of the TBB might be included in the assessment of a priority score in transplant waiting lists. In combination with clinical data and laboratory values, the TBB has the potential to offer guidance in patient management. 6 Furthermore, the present data offer insights into novel molecular pathways involved in the recovery of patients with heart failure. 29 Of the 46 differentially expressed genes (Table 2 ), all were overexpressed in patients who recovered from heart failure. Many overexpressed genes in these patients have RNA or DNA binding functions, eg, RBMS1 and WDR33, playing a crucial role in DNA replication, gene transcription, cell cycle progression, and apoptosis. 30 -32 Various genes with critical regulatory functions were identified, ie, SNRP70; the nuclear transcription factors ELF3, CHES1, and RERE; NSUN4, a gene with methyltrans- Scheme of training and test sets as used for the development of a classifier with prediction analysis of microarrays. All samples obtained from patients with poor prognosis (PP, nϭ18) were selected from a biorepository (nϭ180), and those with good prognosis (GP, nϭ25) were chosen in a case-control fashion (see text for definitions of PP and GP). The classifier, a nearest shrunken centroid, was developed in two thirds of the data (17 samples with GP, 12 samples with PP) with subsequent validation in the remaining one third of data (8 samples with GP, 6 samples with PP). The overall test accuracy of the TBB was calculated from 50 random partitions into training and test sets. ferase activity; and the transcription factor HIF3A. HIF3A has been discussed as an inductor of glucose transporters, vascular endothelial growth factor, and erythropoietin, similar to HIF1A and HIF2A, whereas others postulated its counteraction with the other 2 subunits. 33, 34 The genes CUGBP2, LUC7-like, and SEMA3B are involved in neuromuscular development, axon guidance, and regulation of heart contractility (http://www.geneontology-.org/). Closely related in its function is the overexpressed obscurin-like 1 gene (OBSL1), a linker that stabilizes cell contacts and organelles within the cytoskeleton 35 and that is located at the intercalated discs in the adult cardiomyocyte. 35 OBSL1 is supposed to have similar functions to obscurin, a multifunctional protein responsible for assembly of myofibrils and myocyte cellular organization. 36 By its interaction with titin and ankyrin, 36 as well as by linking sarcomere and sarcoplasmic reticulum, 36 it provides the required alignments for contraction. 36 Furthermore, we discovered 2 genes previously implicated in regenerative pathways, Rad50 and SMG6, important key regulators in telomerase activity and DNA repair. 37 Rad50 is part of the Mre11/Rad50/Nbs1 (MRN) complex, 37 a functional unit that generates t loops by inserting 3Ј G overhangs at human telomere ends. 37 These t loops prevent chromosome ends from being recognized as damaged DNA and provide a template for telomerase and preservation of genome stability. 38 The increase in telomerase activity might explain a protective effect against degenerative processes and aging in the hearts of patients with good prognosis. It is attractive to speculate that the reason for better recovery might be increased cellular regenerative capacity, 39, 40 given observations that Rad50 is essential for viability of stem cells. 38 Of note, 3 genes (SNRP70, OBSL1, and RBMS1) reported here were also reported in a study of 199 human LVAD samples that suggested genes involved in recovery. 23 There was no overlap with results published by Lowes et al, 41, 42 who investigated genes that were overexpressed during recovery from heart failure. This may suggest that there are important differences between gene expression changes caused by therapy and characteristics of gene expression that may predict clinical outcome.
Validation of microarray experiments is an issue of considerable importance. In this context, it remains highly controversial whether independent RNA quantification is essential. Given the technical approach and motivation to avoid RNA amplification, we lacked sufficient RNA for independent reverse-transcription polymerase chain reaction quantification. Recent technical advances, however, obviate 
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Transcriptomic Biomarker in Heart Failurethe need for polymerase chain reaction-based validation in clinical prediction studies. Indeed, the HG-U133 Plus 2.0 Gene Chip has been shown to perform with high consistency compared with established quantitative gene expression platforms. 43, 44 Moreover, numerous published studies have not used independent RNA quantification for validation. In this regard, recent TBB studies in oncology 45, 46 have used splitsample validation, which was the approach used in the present study. Additional validation of selected transcripts by reverse-transcription polymerase chain reaction was not considered mandatory, because the individual expression value of a single gene has less predictive power than the averaged overall gene expression pattern of a molecular signature. 7, 47 Although endomyocardial biopsy is a low-risk procedure, 48 alternative methods for obtaining transcriptomic biomarkers might be developed. 5 There is evidence that affected tissue and circulating blood cells share a high percentage of common genes. 6, 49 Easy accessibility of peripheral blood mononuclear cells by a simple venous puncture makes those cells very attractive for clinical application. 5, 6, 47 Several studies have proven a remarkably high correlation between the gene expression profiles of peripheral blood mononuclear cells and various tissues, 6, 49 and first diagnostic kits, based on blood samples, are commercially available. 6 Future studies will show whether the biopsy-derived biomarkers are also present in the corresponding peripheral blood mononuclear cells of patients, whether peripheral blood mononuclear cell-derived markers perform even better, or whether a combination of both can potentiate the overall accuracy. Future studies will be also necessary to compare the utility of the transcriptomic biomarker in combination with existing biomarkers (eg, brain natriuretic peptide, 18 uric acid 17 ) and established prediction algorithms (artificial neural networks, the Seattle Heart Failure Model 9 ). As a result of frequent comorbidity in patients with cardiomyopathy, a comprehensive profile of laboratory values and clinical data may be necessary for accurate prediction of an individual's prognostic outcome.
Although the present study is one of the most extensive transcriptomic studies of heart tissue, the fact that the patient sample size was much smaller than the measured markers (Ͼ40 000 transcripts per sample) raises important statistical challenges. 7, 26, 50 Power calculations are particularly challenging in this scenario, largely because the variance of each gene contained within the biomarker is impossible to assess, but learning-curve modulations 26 have led to a general recommendation that samples of 20 to 30 in the training set are adequate. Nevertheless, logistic regression models indicate that under these circumstances, the probability of developing a nonrepresentative prediction algorithm rises. 7 Sophisticated statistical modeling, however, indicates that several issues and approaches mitigate this problem. 50 First, if the number of genes included in the predictive biomarker as predictors can be reduced to Ͻ50 and can be chosen according to evidence of differences in gene expression, methods of classification may be applied successfully. 50 Critical to this approach is the practice of validating the biomarker obtained in the training set in an independent test set. The ultimate validation of a successful TBB requires prospective study in an independent clinical trial, an approach highly successful in various cancers. 7, 26 In addition to the sample size issue, another study limitation that warrants mention is that some patients were lost to follow-up, and prognostic information was retrieved solely from the Social Security Death Index. Consequently, we were not able to assess echocardiographic data in all patients. Prospective studies are under way to address this issue.
In summary, we have developed a novel transcriptomic biomarker for prognosis in heart failure that is obtainable from a single EMB with potential for a direct clinical application. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.
